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AIM: To determine whether the association of β-blockers with endoscopic treatment
is superior to endoscopic treatment alone for the secondary prophylaxis of
oesophageal variceal bleeding., METHODS: Randomised controlled trials comparing
sclerotherapy (SCL) with SCL plus β-blockers (BB) or banding ligation (BL) with BL
plus BB were identified. Main outcomes were overall and 6, 12 and 24 mo
rebleeding rates, as well as overall and 6, 12 and 24 mo mortality. Two statistical
methods were used: Yusuf-Peto, and Der Simonian and Laird. Inter-trial
heterogeneity was systematically taken into account., RESULTS: Seventeen
randomised controlled trials were included, 14 with SCL and 3 with BL.
Combination β-blocker and endoscopic treatment significantly reduced rebleeding
rates at 6, 12 and 24 mo and overall [odds ratio (OR): 2.20, 95% confidence interval
(CI): 1.69-2.85, P < 0.0001] compared to endoscopic treatment alone. Mortality at
24 mo was significantly lower for the combined treatment group (OR: 1.83, 95% CI:
1.16-2.90, P = 0.009), as well as overall mortality (OR: 1.43, 95% CI: 1.03-1.98, P =
0.03)., CONCLUSION: Combination therapy should thus be recommended as the
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